CLINICAL TRIALS PROFILE FOR HYTRIN

All Clinical Trials for HYTRIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00449683 ↗	Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin	Completed	National Alliance for Research on Schizophrenia and Depression	Phase 4	2007-03-01	The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antidepressant. This study is for people who take an antidepressant due to a depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks, with one week of baseline measurement and four weeks of treatment with the study medication. The study is based on the hypothesis that terazosin will be effective in reducing the severity of excessive sweating caused by antidepressant treatment, and will have minimal side-effects.
NCT00449683 ↗	Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin	Completed	Thomas Jefferson University	Phase 4	2007-03-01	The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antidepressant. This study is for people who take an antidepressant due to a depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks, with one week of baseline measurement and four weeks of treatment with the study medication. The study is based on the hypothesis that terazosin will be effective in reducing the severity of excessive sweating caused by antidepressant treatment, and will have minimal side-effects.
NCT02244255 ↗	FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia	Completed	Boehringer Ingelheim	Phase 4	1998-08-01	1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the signs and symptoms of benign prostatic hyperplasia (BPH) 2. To evaluate patient's tolerability to the use of FLOMAX® capsules 0.4 mg daily in comparison to HYTRIN® capsules, 5 mg (with titration) daily for the treatment of the symptoms of benign prostatic hyperplasia
NCT03905811 ↗	Terazosin for Parkinson's Disease	Completed	University of Iowa	Phase 1/Phase 2	2019-09-24	The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.

Clinical Trial Conditions for HYTRIN

Condition Name

Condition Name for HYTRIN
Intervention	Trials
Healthy	1
Hyperhidrosis	1
Parkinson Disease	1
Prostatic Hyperplasia	1

Condition MeSH

Condition MeSH for HYTRIN
Intervention	Trials
Hyperhidrosis	1
Parkinson Disease	1
Signs and Symptoms	1
Prostatic Hyperplasia	1

Clinical Trial Locations for HYTRIN

Trials by Country

Trials by Country for HYTRIN
Location	Trials
United States	3

Trials by US State

Trials by US State for HYTRIN
Location	Trials
Iowa	2
Pennsylvania	1

Clinical Trial Progress for HYTRIN

Clinical Trial Phase

Clinical Trial Phase for HYTRIN
Clinical Trial Phase	Trials
Phase 4	2
Phase 1/Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for HYTRIN
Clinical Trial Phase	Trials
Completed	3
Recruiting	1

Clinical Trial Sponsors for HYTRIN

Sponsor Name

Sponsor Name for HYTRIN
Sponsor	Trials
University of Iowa	2
National Alliance for Research on Schizophrenia and Depression	1
Thomas Jefferson University	1

Sponsor Type

Sponsor Type for HYTRIN
Sponsor	Trials
Other	7
Industry	1